Eyal Rubin
2020
In 2020, Eyal Rubin earned a total compensation of $920.1K as Senior Vice President, Chief Financial Officer at Protalix BioTherapeutics, a 497% increase compared to previous year.
Compensation breakdown
| Bonus | $92,646 |
|---|---|
| Option Awards | $43,023 |
| Salary | $303,540 |
| Stock Awards | $382,191 |
| Other | $98,699 |
| Total | $920,099 |
Rubin received $382.2K in stock awards, accounting for 42% of the total pay in 2020.
Rubin also received $92.6K in bonus, $43K in option awards, $303.5K in salary and $98.7K in other compensation.
Rankings
In 2020, Eyal Rubin's compensation ranked 8,970th out of 13,090 executives tracked by ExecPay. In other words, Rubin earned more than 31.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,970 out of 13,090 | 32nd |
Division Manufacturing | 3,834 out of 5,620 | 32nd |
Major group Chemicals And Allied Products | 1,550 out of 2,253 | 31st |
Industry group Drugs | 1,353 out of 1,953 | 31st |
Industry Biological Products, Except Diagnostic Substances | 312 out of 411 | 24th |
Source: SEC filing on April 29, 2022.
Rubin's colleagues
We found two more compensation records of executives who worked with Eyal Rubin at Protalix BioTherapeutics in 2020.
News
Protalix BioTherapeutics CEO Dror Bashan's 2023 pay jumps 83% to $2.7M
April 29, 2024
Protalix BioTherapeutics CEO Dror Bashan's 2022 pay jumps 27% to $1.5M
May 18, 2023
Protalix BioTherapeutics CEO Dror Bashan's 2021 pay slips 14% to $1.2M
April 29, 2022
Protalix BioTherapeutics CEO Moshe Manor's 2019 pay slips 14% to $616K
April 15, 2020